Dendritic cell vaccines for cancer therapy: Fundamentals and clinical trials

Página do item simplificado
dc.contributor.authorRomagnoli, Graziela Gorete [UNESP]
dc.contributor.authorKaneno, Ramon [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionOeste Paulista University - UNOESTE
dc.date.accessioned2023-07-29T13:42:48Z
dc.date.available2023-07-29T13:42:48Z
dc.date.issued2020-09-24
dc.description.abstractSince conventional chemo- and radiotherapy and surgery are not completely satisfactory to fight cancer, active and passive immunotherapeutic approaches have figured as effective agents of customized medicine. Dendritic cells (DCs) are key cells to trigger an effective antitumor response, being the only antigen-presenting cells (APCs) able to prime naïve T lymphocytes for tumor antigens. Therefore, several approaches have been proposed to use these cells as therapeutic antitumor vaccines. Different strategies of tumor antigen delivery, as well as the use of the best DC activators, are in constant search for the development of more immunogenic DC-based vaccines. In the present chapter, we reviewed the strategies for developing clinical-grade DC vaccines and the data of clinical trials with patients with selected types of cancer. Current studies show positive but not definitive results, indicating that the association with other immunotherapeutic agents, such as checkpoint blockers, or even chemotherapeutic agents may contribute to achieve the clinical regression of cancer.en
dc.description.affiliationDepartment of Pathology School of Medicine of Botucatu UNESP - São Paulo State University
dc.description.affiliationDepartment Health Science Oeste Paulista University - UNOESTE
dc.description.affiliationDepartment of Chemical and Biological Sciences Institute of Biosciences of Botucatu UNESP São Paulo State University
dc.description.affiliationUnespDepartment of Pathology School of Medicine of Botucatu UNESP - São Paulo State University
dc.description.affiliationUnespDepartment of Chemical and Biological Sciences Institute of Biosciences of Botucatu UNESP São Paulo State University
dc.format.extent349-364
dc.identifierhttp://dx.doi.org/10.1007/978-3-030-50287-4_18
dc.identifier.citationCancer Immunology: Bench to Bedside Immunotherapy of Cancers, Second Edition, p. 349-364.
dc.identifier.doi10.1007/978-3-030-50287-4_18
dc.identifier.scopus2-s2.0-85148483633
dc.identifier.urihttp://hdl.handle.net/11449/248393
dc.language.isoeng
dc.relation.ispartofCancer Immunology: Bench to Bedside Immunotherapy of Cancers, Second Edition
dc.sourceScopus
dc.subjectAntitumor immunity
dc.subjectCancer
dc.subjectDendritic cell vaccines
dc.subjectImmunomodulation
dc.subjectImmunotherapy
dc.titleDendritic cell vaccines for cancer therapy: Fundamentals and clinical trialsen
dc.typeCapítulo de livro

Arquivos

Coleções

Artigos - Patologia - FMB